A transdermal therapeutic system comprising a self-adhesive matrix layer containing the free base (−)-5,6,7,8-tetrahydro-6-[propyl-1[2-(2-thienyl)ethyl]amino]-1-naphthalenol in an amount effective for the treatment of the symptoms of Parkinson's drome, wherein the matrix is based on a an acrylate-based or silicone-based polymer adhesive system having a solubility of ≧5% (w/w) for the free base (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]-amino]-1-naphthalenol, all of said free base being present in the matrix in the absence of water; a backing layer inert to the components of the matrix layer; and a protective foil or sheet covering the matrix layer to be removed prior to use. view more

The transdermal therapeutic system of claim 1 wherein the silicone-based polymer adhesive in the matrix layer further comprises additives to enhance the solubility of (−)-5,6,7,8-tetrahydro-6-[propyl-[2-(2-thienyl)ethyl]amino]-1-naphthalenol in the form of hydrophilic polymers or glycerol or glycerol derivatives. view more

The transdermal therapeutic system of claim 5 wherein the silicone-based polymer adhesive contains between 5 to 25% (w/w) (−)-5,6,7,8-tetrahydro[propyl-[2-(2-thienyl)ethyl]-amino]-1-naphthalenol.

The transdermal therapeutic system of claim 5, wherein the hydrophilic polymer is selected from the group of polyvinylpyrrolidone, a copolymer of vinylpyrrolidone and vinylacetate, polyethyleneglycol, polypropylene glycol, and a copolymer of ethylene and vinylacetate. view more

The transdermal therapeutic system of claim 14 wherein the hydrophilic polymer is soluble polyvinylpyrrolidone, and wherein the soluble polyvinylpyrrolidone is present in the active substance-containing matrix layer at a concentration of between 1.5 and 5% (w/w). view more

A polymorphic form of rotigotine characterized by at least one parameter selected from the group consisting of: (a) a powder X-ray diffraction spectrum comprising at least one peak at the following ° 2θ angles (±0.2): 12.04, 13.68, 17.72, and 19.01; (b) a Raman spectrum comprising at least one peak at the following (±3 cm⁻¹): 226.2, 297.0, 363.9, 737.3, 847.3, 1018.7, and 1354.3 cm⁻¹ (c) a DSC peak with a T_onset at 97° C.±2° C. measured with a heating rate of 10°/min; and (d) a melting point of 97° C.±2° C. view more

The polymorphic form of rotigotine of claim 1, wherein the polymorphic form of rotigotine is characterized by at least the following powder X-ray diffraction peaks at ° 2θ angles (±0.2): 12.04, 13.68, 17.72 and/or 19.01.

A polymorphic form of rotigotine having a powder X-ray diffraction spectrum substantially as shown in <figref idref="DRAWINGS">FIG. 1</figref>.